Phase II Randomized Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Olanzapine (Primary) ; Ondansetron (Primary) ; Aprepitant
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- Acronyms OlaCINV
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 02 Jul 2018 Planned primary completion date changed from 14 Mar 2019 to 25 May 2019.
- 29 Mar 2018 New trial record